Clinical trials
catalyst calendar across sponsors →Studies where EQ is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
3 interventional · 1 with posted results
Held by 7 tracked-famous managers (RENAISSANCE TECHNOLOGIES LLC, Balyasny Asset Management L.P., TWO SIGMA INVESTMENTS, LP, CITADEL ADVISORS LLC, JANE STREET GROUP, LLC, +2 more) · FINRA short interest 11.8 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 8 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)NCT05263999The efficacy of itolizumab versus placebo as initial therapy for aGVHD in combination with corticosteroids in achieving early disease response.Randomized · Quadruple-masked · Treatment | Phase 3 | Terminatedsponsor's stated reason: The FDA declined to grant Breakthrough Therapy designation or support an Accelerated Approval pathway based on the EQUATOR study data. | Biological: Itolizumab · Drug: EQ001 Placebo | Graft Versus Host Disease, GVHD, Acute-graft-versus-host Disease, Acute GVHD, aGVHD | 158 | 2025-04-22actual | 2025-06-17 |
| Study of EQ101 in Adult Subjects With Moderate to Severe Alopecia AreataNCT05589610results2025-04-10Number of Treatment Emergent Adverse EventsOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: EQ101 | Alopecia Areata, Alopecia, Alopecia Totalis, Alopecia Universalis | 36 | 2024-03-26actual | 2025-04-10 |
| Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia AreataNCT03532958Change from baseline using the Severity of Alopecia Tool (SALT) scoreRandomized · Quadruple-masked · Treatment | Phase 2 | Withdrawnsponsor's stated reason: Transfer of study sponsor | Drug: BNZ-1, Normal saline | Alopecia Areata, Alopecia Totalis, Alopecia Universalis | 0 | Nov 2022 | 2022-09-16 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19